drugset / Trial / NCT01179295
Japanese BAY86-9766 Monotherapy Phase I Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an uncontrolled, open-label, non-randomized phase I / pharmacokinetic study of oral BAY86-9766 to investigate the safety, tolerability, pharmacokinetics, and efficacy profiles in Japanese patients with advanced solid tumors
Timeline
- Start
- 2010-11-19
- Primary completion
- 2012-04-27
- Completion
- 2012-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Refametinib | Small molecule | 30 mg | Oral |
| Subject | Refametinib | Small molecule | 50 mg | Oral |
| Subject | Refametinib | Small molecule | 60 mg | Oral |
| Subject | Refametinib | Small molecule | 100 mg | Oral |